Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization

Diagnostic Molecular Pathology

Volumn 19, Issue 3, 2010, Pages 151-156

  Zhang, Shengle ^a   Pavlovitz, Brian ^a   Tull, Jamie ^a   Wang, Yan ^c   Deng, Fang Ming ^a   Fuller, Christine ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

fluorescence in situ hybridization; prostate carcinoma; TMPRSS2 gene

Indexed keywords

FORMALDEHYDE;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE TRANSLOCATION; GENETIC HETEROGENEITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TMPRSS2 GENE; TUMOR GENE;

ADENOCARCINOMA; EPITHELIUM; GENE DELETION; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PATHOLOGY, MOLECULAR; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANSLOCATION, GENETIC;

EID: 77956245786     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181bb216a     Document Type: Article

References (22)

1. Tallini G, Hui P. Sarcoma. In: Leonard DGB, ed. Molecular Pathology in Clinical Practice. New York: Springer; 2007:287-297.
2. Bagg A. Neoplastic Hematopathology. In: Leonard DGB, ed. Molecular Pathology in Clinical Practice. New York: Springer; 2007:321-396.
3. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
4. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion in prostate cancer. Genes Chromosomes Cancer. 2006;45:717-719.
5. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETC family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538-544.
6. Morri DS, Tomlins SA, Montie JE, et al. The discovery and application of gene fusions in prostate cancer. BJU Int. 2008; 102:276-282.
7. Yoshimoto M, Joshua AM, Chilton-MacNeill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006;8:465-469.
8. Perner S, Mosquera J-M, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888.
9. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 2007;20:921-928.
10. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826-832.
11. Furusato B, Gao C-L, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21:67-75.
12. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67:7991-7995.
13. Teixeira MR. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. Am J Surg Pathol. 2008;31:882-888.
14. Mehra S, dela Roza G, Tull J, et al. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation. Diagn Mol Pathol. 2008;17:14-20.
15. Yoshimoto M, Ludkovski O, Bayani J, et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2: ERG prostate cancer gene fusion. Genes Chromosomes Cancer. 2007;46:861-863.
16. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene. 2008;27:1993-2003.
17. Barry M, Perner S, Demichelis F, et al. TMPRRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007;70:630-633.
18. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596-4599.
19. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. 2007;6:40-45.
20. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68:9629-9637.
21. Hermans KG, Bressers AA, van der Korput H, et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008;68:3094-3098.
22. Rubin MA. Targeted therapy of cancer: new role for pathologists-prostate cancer. Mod Pathol. 2008;21(suppl 2):S44-S55.